Real-world of Nintedanib in a Spanish non-IPF progressive pulmonary fibrosis cohort

被引：0

作者：

Vicens Zygmunt, Vanesa ^{[1
]}

Bordas-Martinez, Jaume ^{[1
]}

Munoz-Bolano, Miriam ^{[2
]}

Carmezim-Correia, Joao ^{[3
]}

Belen Llanos-Gonzalez, Ana ^{[4
]}

Domingo-Carnice, Adria ^{[5
]}

Rodriguez-Cumplido, Dolores ^{[5
]}

Bermudo-Peloche, Guadalupe ^{[1
]}

Tebe-Cordomi, Cristian ^{[6
]}

Llop-Rius, Roser ^{[5
]}

Molina-Molina, Maria ^{[7
]}

机构：

[1] Univ Hosp Bellvitge, ILD Unit, Barcelona, Spain

[2] Univ Hosp Bellvitge, Barcelona, Spain

[3] Bellvitge Biomed Res Inst IDIBELL, Biostatist Unit UBiDi, Barcelona, Spain

[4] Univ Complex Hosp Canarias, ILD Unit, Santa Cruz De Tenerife, Spain

[5] Univ Hosp Bellvitge, Barcelona, Spain

[6] Bellvitge Biomed Res Inst IDIBELL, Biostat Unit UBiDi, Barcelona, Spain

[7] Univ Hosp Bellvitge, ILD Unit, Barcelona, Spain

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

关键词：

D O I：

10.1183/13993003.congress-2023.PA408

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[21] Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
Rivera-Ortega, Pilar
Hayton, Conal
Blaikley, John
Leonard, Colm
Chaudhuri, Nazia
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
[22] A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Anna J. Podolanczuk
Vincent Cottin
Advances in Therapy, 2023, 40 : 2038 - 2050
[23] REAL-WORLD TOLERABILITY STUDY OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE COMPARED TO PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
Newman, K.
Gadoot, T.
Stranks, L.
Morris, H.
Zakis, K.
Swale, J.
Greaves, M.
Stanel, S.
Ramjug, S.
Avram, C.
Blaikley, J.
Leonard, C.
Hayton, C.
Rivera-Ortega, P.
THORAX, 2022, 77 : A96 - A96
[24] Implications Of Pulmonary Physiology And Exercise Testing Results In Idiopathic Pulmonary Fibrosis (ipf) In A Real World Cohort
Sharp, C.
Dixon, G.
Edwards, A.
Adamali, H.
Millar, A. B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
[25] Prognosis in Non-IPF with Progressive Fibrotic Phenotype Results in Similar Prognosis in IPF
Ito, T.
Takei, R.
Sasano, H.
Yamano, Y.
Yokoyama, T.
Matsuda, T.
Kimura, T.
Furukawa, T.
Johkoh, T.
Fukuoka, J.
Kondoh, Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
[26] Pirfenidone And Nintedanib For Pulmonary Fibrosis In Real-World Clinical Practice: Tolerability And Adverse Drug Reactions
Galli, J. A.
Pandya, A.
Vega-Olivio, M.
Criner, G.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
[27] Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world
Ogura, Takashi
Kitamura, Hideya
RESPIROLOGY, 2017, 22 (06) : 1051 - 1052
[28] MMP28 Is Upregulated in Idiopathic Pulmonary Fibrosis (IPF) Epithelium and Is a Promising Biomarker to Distinguish IPF from Non-IPF Patients
Maldonado, M.
Buendia, I.
Vicens Zygmunt, V.
Planas, L.
Molina Molina, M.
Selman, M.
Pardo, A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[29] Characterizing Progressive Pulmonary Fibrosis in a Multi-center Real World Cohort
Swaminathan, A. C.
Stevens, S. R.
Burg, C. A.
Best, J. H.
Kennedy, C. C.
Scholand, M.
Horowitz, J. C.
Lipchik, R. J.
Soskis, A.
Aronson, K. I.
Marsolo, K.
Gebre, E.
Qualls, L.
Palmer, S. M.
Wruck, L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[30] Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases
Belen Llanos-Gonzalez, Ana
Bordas Martinez, Jaume
Bermudo Peloche, Guadalupe
Suarez-Cuartin, Guillermo
Vicens Zygmunt, Vanesa
Planas-Cerezales, Lurdes
Palma Lopez, Jose Manuel
Perez Martin, Laura
Jodar Masanes, Ramon
Padulles Zamora, Nuria
Garcia Gil, Sara
Dorca Sargatal, Jordi
Medina Gonzalvez, Agustin
Acosta Fernandez, Orlando
Molina Molina, Maria
EUROPEAN RESPIRATORY JOURNAL, 2019, 54

← 1 2 3 4 5 →